J Drugs Dermatol
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Tofacitinib is a novel, oral Janus kinase inhibitor currently under investigation for plaque psoriasis. ⋯ Short-term (12-week) treatment with oral tofacitinib produced clinical improvement across all body regions assessed in patients with moderate-to-severe plaque psoriasis, including areas typically non-responsive to treatment.